Related Experiment Video
Updated: Mar 19, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Anti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers
Heping Yan1, Vaishali Kapoor1, Kim Nguyen1
1Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri, USA.
Abstract:
Radiation-inducible neo-antigens are proteins expressed on cancer cell surface after exposure to ionizing radiation (IR). These neo-antigens provide opportunities to specifically target cancers while sparing normal tissues. Tax interacting protein-1 (TIP-1) is induced by irradiation and is translocated to the surface of cancer cells. We have developed a monoclonal antibody, 2C6F3, against TIP-1.Epitope mapping revealed that 2C6F3 binds to the QPVTAVVQRV epitope of the TIP-1 protein. 2C6F3 binds to the surface of lung cancer (A549, LLC) and glioma (D54, GL261) cell lines. 2C6F3 binds specifically to TIP-1 and ELISA analysis showed that unconjugated 2C6F3 efficiently blocked binding of radiolabeled 2C6F3 to purified TIP-1 protein. To study in vivo tumor binding, we injected near infrared (NIR) fluorochrome-conjugated 2C6F3 via tail vein in mice bearing subcutaneous LLC and GL261 heterotopic tumors. The NIR images indicated that 2C6F3 bound specifically to irradiated LLC and GL261 tumors, with little or no binding in un-irradiated tumors.We also determined the specificity of 2C6F3 to bind tumors in vivo using SPECT/CT imaging. 2C6F3 was conjugated with diethylene triamine penta acetic acid (DTPA) chelator and radiolabeled with 111Indium (111In). SPECT/CT imaging revealed that 111In-2C6F3 bound more to the irradiated LLC tumors compared to un-irradiated tumors. Furthermore, injection of DTPA-2C6F3 labeled with the therapeutic radioisotope, 90Y, (90Y-DTPA-2C6F3) significantly delayed LLC tumor growth. 2C6F3 mediated antibody dependent cell-mediated cytotoxicity (ADCC) and antibody dependent cell-mediated phagocytosis (ADCP) in vitro.In conclusion, the monoclonal antibody 2C6F3 binds specifically to TIP-1 on cancer and radio-immunoconjugated 2C6F3 improves tumor control.
Insights
A novel monoclonal antibody, 2C6F3, targets radiation-inducible neo-antigens like Tax interacting protein-1 (TIP-1) on cancer cells. Radio-immunoconjugates of 2C6F3 demonstrate specific tumor targeting and significantly inhibit tumor growth, offering a new cancer therapy approach.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Radiation-inducible neo-antigens on cancer cells offer targeted therapy opportunities.
- Tax interacting protein-1 (TIP-1) is a radiation-induced surface protein on cancer cells.
Purpose of the Study:
- To develop and characterize a monoclonal antibody against TIP-1 for cancer targeting.
- To evaluate the in vitro and in vivo efficacy of the anti-TIP-1 antibody and its radio-immunoconjugates.
Main Methods:
- Developed monoclonal antibody 2C6F3 targeting the TIP-1 epitope QPVTAVVQRV.
- Utilized Near-Infrared (NIR) and SPECT/CT imaging to assess in vivo tumor binding.
- Conjugated 2C6F3 with chelators (DTPA) and radiolabeled with 111In and 90Y for imaging and therapy.
Main Results:
- 2C6F3 specifically binds to TIP-1 on lung cancer and glioma cell lines.
- In vivo studies confirmed specific binding of 2C6F3 to irradiated tumors.
- 90Y-labeled 2C6F3 significantly delayed tumor growth in mice, demonstrating therapeutic potential.
Conclusions:
- Monoclonal antibody 2C6F3 is a specific targeting agent for radiation-induced TIP-1 on cancer cells.
- Radio-immunoconjugates of 2C6F3 show promise for targeted cancer imaging and therapy, improving tumor control.
More Related Videos
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Tumor Immunotherapy